- Name: Yu-Pei Chen
- Title: Chief Physician, Principal Investigator
- Email: chenyup1@sysucc.org.cn
- Phone:
Dr. Yu-Pei Chen, is Chief Physician, Principal Investigator, and PhD Supervisor in the Department of Radiation Oncology at Sun Yat-sen University Cancer Center, and Principal Investigator at the State Key Laboratory of Oncology in South China. His research focuses on the precision therapeutic strategies for nasopharyngeal carcinoma (NPC).
He has published numerous first- or corresponding-author papers in leading journals, including The Lancet (×3), Annals of Oncology (×2), Cell Research, Nature Medicine, Cancer Cell, Journal of Clinical Oncology, Science Advances, and Med, among others. Five of his publications have been recognized as ESI Highly Cited Papers (top 1%), and one as an ESI Hot Paper (top 0.1%).
He currently serves as Co-Chair of the NPC Guideline Committee of the Chinese Society of Clinical Oncology–American Society of Clinical Oncology (CSCO–ASCO), and Vice Chair of the China NPC Committee of the National Comprehensive Cancer Network (NCCN), among other professional appointments.
Dr. Chen has been selected for several prestigious talent programs and honors, including the Ministry of Education High-Level Young Talent Program, the He Xiangjian Young Scientist Program, and MIT Technology Review Innovators Under 35 (Asia Pacific). He has also been listed among the Stanford–Elsevier World’s Top 2% Scientists for five consecutive years (2021–2025).
His awards include the Ministry of Education Outstanding Young Research Achievement Award, the Wu Mengchao Medical Youth Science Fund Award, the Young Scientist Award of the Chinese Anti-Cancer Association, the Huaxia Youth Medical Science and Technology Award, China’s Top 10 Advances in Life Sciences, and the People’s Daily “Outstanding Physician” Award.
The research focus of Dr. Yu-Pei Chen centers on the comprehensive treatment and precision medicine of nasopharyngeal carcinoma (NPC). Design and conduct of phase II and III clinical trials in the field of NPC. Preclinical basic researches focusing on biomarkers, prognostic molecules, and signal pathways related with the development of NPC.
09/2015-06/2017 M.D., Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China
09/2009-09/2015 Bachelor, Sun Yat-sen University, Guangzhou, China
1. Chen, Yu-Pei(#); Liu, Xu(#); Zhou, Qin(#); Yang, Kun-Yu(#); Jin, Feng(#); Zhu, Xiao-Dong(#); Shi, Mei(#); Hu, Guo-Qing(#); Hu, Wei-Han(#); Sun, Yan; Wu, Hong-Fen; Wu, Hui; Lin, Qin; Wang, Hui; Tian, Ye; Zhang, Ning; Wang, Xi-Cheng; Shen, Liang-Fang; Liu, Zheng-Zheng; Huang, Jing; Luo, Xiu-Ling; Li, Ling; Zang, Jian; Mei, Qi; Zheng, Bao-Min; Yue, Dan; Xu, Jing; Wu, San-Gang; Shi, Yan-Xia; Mao, Yan-Ping; Chen, Lei; Li, Wen-Fei; Zhou, Guan-Qun; Sun, Rui; Guo, Rui; Zhang, Yuan; Xu, Cheng; Lv, Jia-Wei; Guo, Ying; Feng, Hui-Xia; Tang, Ling-Long(*); Xie, Fang-Yun(*); Sun, Ying(*); Ma, Jun(*). Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet, 2021, 398(10297): 303-313.
2. Chen, Yu-Pei(#); Chan, Anthony TC; Le, Quynh-Thu; Blanchard, Pierre; Sun, Ying(*); Ma, Jun(*). Nasopharyngeal carcinoma. Lancet, 2019, 2019, 394(10192): 64-80.
3. Chen, Yu-Pei(#); Wang, Ya-Qin(#); Lv, Jia-Wei(#); Li, Ying-Qin(#); Chua, Melvin; Le, Quynh-Thu; Lee, Nancy; Colevas, A. Dimitrios; Seiwert, Tanguy; Hayes, D. Neil; Riaz, Nadeem; Vermorken, Jan B; O'Sullivan, Brian; He, Qing-Mei; Yang, Xiao-Jing; Tang, Ling-Long; Mao, Yan-Ping; Sun, Ying; Liu, Na(*); Ma, Jun(*). Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Ann Oncol, 2019, 30(1): 68-75.
4. Chen, Yu-Pei(#); Ismaila, Nofisat; Chua, Melvin LK; Colevas, A. Dimitrios; Haddad, Robert; Huang, Shao Hui; Wee, Joseph TS; Whitley, Alexander C; Yi, Jun-Lin; Yom, Sue S; Chan, Anthony TC; Hu, Chao-Su; Lang, Jin-Yi; Le, Quynh-Thu; Lee, Anne WM; Lee, Nancy; Lin, Jin-Ching; Ma, Brigette; Morgan, Thomas J; Shah, Jatin; Sun, Ying(*); Ma, Jun(*). Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II to IVA nasopharyngeal carcinoma: CSCO and ASCO guideline. J Clin Oncol, 2021, 39(7): 840-859.
5. Chen, Yu-Pei(#); Yin, Jian-Hua(#); Li, Wen-Fei(#); Li, Han-Jie(#); Chen, Dong-Ping(#); Zhang, Cui-Juan(#); Lv, Jia-Wei; Wang, Ya-Qin; Li, Xiao-Min; Li, Jun-Yan; Zhang, Pan-Pan; Li, Ying-Qin; He, Qing-Mei; Yang, Xiao-Jing; Lei, Yuan; Tang, Ling-Long; Zhou, Guan-Qun; Mao, Yan-Ping; Wei, Chen; Xiong, Ke-Xu; Zhang, Hong-Bo; Zhu, Shi-Da; Hou, Yong; Sun, Ying; Dean, Michael; Amit, Ido; Wu, Kui(*); Kuang, Dong-Ming(*); Li, Gui-Bo(*); Liu, Na(*); Ma, Jun(*). Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res, 2020, 30(11): 1024-1042.
6. Wang, Ya-Qin(#); Wu, Dong-Hong(#); Wei, Deng-Hui(#); Shen, Jia-Yi(#); Huang, Zi-Wei(*); Liang, Xiao-Yu; Cho. William CS; Ma, Jun; Lv, Jia-Wei(*); Chen, Yu-Pei(*). TEAD4 is a master regulator of high-risk nasopharyngeal carcinoma. Sci Adv, 2023, 9(1): eadd0960.
7. Zhao, Yin(#); Huang, Shen-Yan(#); Tan, Xi-Rong; Long, Liu-Fen; He, Qing-Mei; Liang, Xiao-Yu; Bai, Jie-Wen; Li, Qing-Jie; Lin, Jia-Yi; Li, Ying-Qin; Liu, Na; Ma, Jun(*); Chen, Yu-Pei(*). N6-Methyladenosine-Modified CBX1 Regulates Nasopharyngeal Carcinoma Progression Through Heterochromatin Formation and STAT1 Activation. Adv Sci, 2022, 9(36): e2205091.
8. Liu, Xu(#); Zhang, Yuan(#);Yang, Kun-Yu(#); Zhang, Ning(#); Jin, Feng(#); Zou, Guo-Rong(#); Zhu, Xiao-Dong(#); Xie, Fang-Yun(#); Liang, Xiao-Yu (#); Li, Wen-Fei; He, Zhen-Yu; Chen, Nian-Yong; Hu, Wei-Han; Wu, Hai-Jun; Shi, Mei; Zhou, Guan-Qun; Mao, Yan-Ping; Guo, Rui; Sun, Rui; Huang, Jing; Liang, Shao-Qiang; Wu, Wei-Li; Su, Zhen; Li, Ling; Ai, Ping; He, Yu-Xiang; Zang, Jian; Chen, Lei; Lin, Li; Huang, Shao-Hui; Xu, Cheng; Lv, Jia-Wei; Li, Ying-Qing; Hong, Shu-Bin; Jie, Yu-Sheng; Li, Hao; Huang, Sai-Wei; Liang, Ye-Lin; Wang, Ya-Qin; Peng, Ying-Lin; Zhu, Jin-Han; Zang, Sheng-Bing; Liu, Song-Ran; Lin, Qing-Guang; Li, Hao-Jiang; Tian, Li; Liu, Li-Zhi; Zhao, Hong-Yun; Lin, Ai-Hua; Li, Ji-Bin; Liu, Na; Tang, Ling-Long(*); Chen, Yu-Pei(*); Sun, Ying(*); Ma, Jun(*). Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet, 2024, 403(10445): 2720-2731.
9. Xu, Cheng(#); Chen, Yu-Pei(#); Du Xiao-Jing(#);. Liu Jin-Qi(#); Huang Cheng-Long; Chen Lei; Zhou Guan-Qun; Li Wen-Fei; Mao Yan-Ping; Hsu Chiun; Liu Qing; Lin Ai-Hua; Tang Ling-Long; Sun Ying; Ma Jun(*). Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ, 2018, 363: k4226.
10. Lv, Jiawei (#); Wei, Yuan (#); Yin Jian-Hua (#); Chen, Yu-Pei (#); Zhou, Guan-Qun (#); Wei, Chen (#); Liang, Xiao-Yu (#); Zhang, Yuan(#); Zhang, Cui-Juan; He, Shi-Wei; He, Qing-Mei; Huang, Zhuo-Li; Guan, Jia-Li; Shen, Jia-Yi; Li, Xiao-Min; Li, Jun-Yan; Li, Wen-Fei; Tang, Ling-Long; Mao, Yan-Ping; Guo, Rui; Sun, Rui; Zheng, Yu-Hui; Zhou, Wen-Wen; Xiong, Ke-Xu; Wang, Si-Qi; Jin, Xin; Liu, Na (*); Li, Gui-Bo(*); Kuang, Dong-Ming(*); Sun, Ying(*); Ma, Jun(*). The tumor immune microenvironment of nasopharyngeal carcinoma following gemcitabine plus cisplatin treatment. Nat Med, 2023, 29(6): 1424-1436.